Testing for COVID-19 by Jayathirtha, Yasmin
49— Rediscovering School Science | Oct 2020
COVID-19 is caused by the virus SARS-CoV-2, which belongs  to a family of coronaviruses  
that infect the respiratory tract (see  
Fig. 1). It can be diagnosed by testing 
for the presence of genetic material 
(molecular tests) or proteins (antigen 
tests) specific to the virus, or the body’s 
response (antibody test) to infection  
(see Fig. 2). 
For any test to be useful, it must be 
specific, detecting only the element 
(molecule, antigen or antibody) of 
interest. It should also be sensitive, 
giving positive results even when the 
relevant element is present at low 
concentrations in the sample. In theory, 
a perfect test would have a specificity 
(or true negative rate) and sensitivity 
(or true positive rate) of 100% (see 
Table I). In practice, there are no perfect 
tests. A test with a sensitivity of 99% 
will miss the presence of the antigen 
or antibody of interest in 1 out of 
100 samples tested (1 false negative). 
Similarly, a test with a specificity of 95% 
will incorrectly identify the presence of 
the antigen or antibody in 5 of every 
100 samples (5 false positives). 



















Designed to detect the presence of  
the genetic material of SARS-CoV-2  
in a swab sample, these tests are based  
on a method called Reverse 
Transcription Polymerase Chain 
Reaction or RT-PCR (see Box 1). With a 
sensitivity and specificity that is close 
to 100%, molecular tests set the gold 




How do we detect COVID-19 
infection? What kind of 
samples are needed to test 
infection? What is the 
likelihood of a test result 
being inaccurate? How do 
molecular and antigen tests 
work? When are antibody 
tests effective? Which tests 
would be most effective 
for contact tracing, and 
which for population-wide 
screening?
OUR RESPONSE
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Molecular tests are of two kinds:
(a) Real-time RT-PCR: This is the most 
common molecular test. ‘Real-time’ 
refers to the fact that the concentration 
of a certain molecule (like virus-specific 
DNA) is detected (using fluorescent 
probes) as the test (like the RT-PCR) 
is being run. To do this, some of the 
building blocks added to build new 
strands in the DNA amplification step 
are labelled with fluorescent tags to 
act as probes. As the probes become 
part of new copies of the virus-specific 
DNA, their tags are released into the 
solution. The fluorescence of the solution 
is measured at the end of each cycle. 
When it reaches a level that is known 
to correspond to 35 billion copies of 
DNA, the test is considered positive for 
infection. The number of cycles (Ct) 
(a) A nose or throat swab of potentially 
infected cells is used as a sample for 
molecular or antigen tests.
Credits: ©Raimond Spekking, Wikimedia Commons. 
URL: https://tr.wikipedia.org/wiki/Dosya:Infektions-
schutzzentrum_im_Rautenstrauch-Joest-Muse-
um,_K%C3%B6ln-6313.jpg. License: CC-BY-SA 4.0. 
(b) A blood sample is collected for antibody 
tests.




Fig. 2. Different samples are collected for different tests.
Box 1. How do molecular tests 
work?
In the first step of a molecular test, all the 
RNA in a swab sample (cellular and virus) 
is reverse transcribed into complementary 
DNA molecules. In the second step, only 
DNA sequences specific to the virus are 
amplified through a polymerase chain 
reaction (see Fig. 3). The specificity of 
this step is ensured by the use of specific 
primers. Primers are short stretches of 
DNA that initiate replication by binding 
to a complementary sequence in the 
template. Molecular tests for SARS-CoV-2 
use primers for sequences from two genes 
— the gene for the E protein, and the 
RdRp gene that makes RNA dependant 
RNA polymerase enzyme. Sequencing of 
the SARS-CoV-2 genome shows that both 
genes are unique to the virus and slow to 
mutate. Primers for gene sequences from 
related virus families are used as controls.
If the virus is present in the swab, these 
primers will be able to initiate the 
replication of both gene sequences. Only 
samples that test positive for both genes 
are considered to be true positives for 
COVID-19. Samples that test negative for 
the gene for E protein are considered to 
be true negatives for the infection. Each 
of the 35-40 PCR cycles will double the 
number of these sequences, amplifying 
their concentration manyfold. This allows 
easy detection of even trace amounts of 
the virus in a swab sample.
Fig. 3. The RT-PCR method.




Fig. 1. A simplified view of COVID-19 infection. On entry into a host cell, SARS-CoV-2 
replicates and multiplies. The number of viruses in the body increase with time, and peaks at 
around the time an infected person starts showing symptoms of disease. Our immune system 
responds to the virus by making two kinds of antibodies — called IgM (Immunoglobulin M) 
antibodies & IgG (Immunoglobulin G) antibodies. Both begin to appear at about the same time 
as the first symptoms of disease. IgM antibodies, which lock on to the virus particles and 
prevent them from entering cells, peak a week later. IgG antibodies, which retain ‘memory’ of 
the virus and protect us against reinfection, peak about two weeks after symptoms appear. 
Credits: Siouxsie Wiles & Toby Morris. URL: https://en.wikipedia.org/wiki/File:Covid-19-Time-Course-05.gif. 
License: CC-BY-SA.
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required to reach this number tells us 
what the original viral load was. In India, 
Ct < 35 is positive, Ct > 35 is negative, 
and Ct = 35 suggests that the test needs 
to be repeated. This test is highly specific, 
giving no false positives. It is also very 
sensitive, testing positive even if a single 
virus particle is present in the swab 
sample. But it is time consuming (results 
take a day) and expensive. The sample 
has to be collected and handled carefully 
by specially trained health professionals 
to minimise risk of contamination. It 
has to be transported to a laboratory 
which has uninterrupted power supply 
and air-conditioning for maintenance of 
the real-time RT-PCR machine. Sample 
preparation takes about 2-4 hours, and 
the PCR cycles take about 4-8 hours to 
run. Most accredited laboratories can run 
about 200-300 tests per day, working 
around the clock. Delays in test results 
impact the trace (contacts of an infected 
person), test (each contact), quarantine 
(those who test positive) protocol that 
many countries have adopted to reduce 
spread of infection. Contacts may need 
to be quarantined before their test 
results can be obtained to confirm the 
necessity of this measure. 
(b) TrueNat tests: This test uses chip-
based, indigenously developed, battery 
operated, portable RT-PCR machines 
that were originally designed for contact 
testing for TB and HIV. The swab is 
treated with a lysis buffer (lysis = break 
up) to inactivate the virus and added 
to micro-PCR chips that are preloaded 
with the necessary reagents. Each 
machine can have 1, 2 or 4 channels, 
and each channel can be used to test 
an independent sample. Since these 
tests can be run where the samples 
are collected, the results are available 
sooner. This allows higher testing rates, 
and more localised responses to the 
spread of infection. 
Rapid Antigen Test (RAT)
Designed to detect the presence of virus 
proteins (antigens) that are capable of 
producing an immune response in our 
body, this test is based on a method 
called Lateral Flow Immunoassay or 
LFIA (see Box 2). 
This test is relatively inexpensive and 
quick (results are available in about 30 
minutes), making it particularly suitable 
for contact tracing. On the other hand, 
antibodies against the S protein of 
SARS-CoV-2 can bind to proteins of 
Box 2. How does RAT work? 
An LFIA is designed to be used in a 
dipstick format or in a housed cassette 
(see Fig. 4). Both involve a test strip that 
has a sample pad, a conjugate pad, and a 
nitrocellulose membrane. In a RAT test, the 
conjugate pad has a mixture of two sets 
of antibodies (called primary antibodies) — 
one set can bind to the antigen of interest 
(the S protein of the SARS-CoV-2 virus) 
while the other can bind to a control 
protein that is universally found in human 
blood samples. Both sets of primary 
antibodies are conjugated to dyes. The 
nitrocellulose membrane has two bands of 
immobilised (or capture) antibodies. One 
of them, called the test band, has capture 
antibodies against a different part of the 
antigen of interest. Similarly, the other 
band, called a control band, has capture 
antibodies against a different part of the 
control protein. 
The antigens in a swab or sputum 
(coughed up) sample flow laterally across 
the strip through capillary action. When 
they reach the conjugate pad, one set of 
primary antibodies bind to the control 
protein. If the swab contains infected cells, 
the other set of primary antibodies bind to 
the S protein. When the capture antibodies 
in the test band grab onto the S protein, 
the accumulation of dye molecules in this 
part of the strip causes the test band to 
colour up. Similarly, when the capture 
antibodies in the control band bind to the 
control protein, the control band colours 
up. A sample is considered positive for 
the virus when colour appears in both the 
test and control bands. It is considered 
negative for the virus when colour appears 
only in the control band. If no colour is 
produced in either band, then the test is 
considered invalid.
Fig. 4. The design of a lateral flow immunoassay.
Credits: U.S. National Aeronautics and Space Administration, Wikimedia Commons. 
URL: https://commons.wikimedia.org/wiki/File:Lateral_Flow_Assay.jpg#filehistory. License: CC-BY.
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other coronaviruses, increasing the 
likelihood of false negatives. Also, 
since it does not involve any kind of 
amplification, the antigen needs to 
be present in sufficient quantities 
in a swab for it to be detected. As a 
result, the specificity of this test can 
vary from 80-90%, and sensitivity can 
range from 34-90%. This means that a 
molecular test is needed to confirm a 
negative RAT result. But a positive RAT 
result is considered a true positive for 
the virus. Such patients (about 50% 
of those found infected according to 
some reports) can get into isolation 
faster, reducing the chances of spread 
of the disease.
Antibody Tests
Doctors and scientists studying a 
pandemic explore several questions 
— how many people are infected by 
the virus at any given point of time? 
How many remain asymptomatic? How 
many develop symptoms early, and how 
many have delayed onset of symptoms? 
Can someone who has recovered 
from a COVID-19 infection catch the 
infection again? In addition, scientists 
use contact tracing to find out how 
the virus spreads. This knowledge 
allows health care teams to advise 
governments on controlling spread 
of the disease, and advise people on 
measures to remain safe. Molecular and 
antigen tests can only indicate current 
infections. Antigen tests generally pick 
up signs of infection in only those who 
have severe symptoms. But we know 
that many of those who are infected 
may be asymptomatic or have such 
mild symptoms that they never get 
tested. Antibody tests help us develop 
a better understanding of these aspects 
of the pandemic.
Antibody tests are designed to detect 
the presence of the IgM and IgG 
antibodies in blood serum or plasma 
samples. They are of two kinds: 
 z The most common antibody 
test is based on the Enzyme Linked 
Immunosorbent Assay or ELISA 
technique (see Box 3). This test can 
detect the presence of virus-specific 
antibodies with a high degree of 
accuracy. But because it requires a lab 
setting, it is relatively time-intensive 
and expensive. 
 z A rapid serology antibody test, 
like a RAT, is based on the lateral 
flow immunoassay technique. It is 
quick (test results are available in 15 
minutes), relatively inexpensive, and 
can be conducted at point-of-care. 
Since it can be used to screen a large 
number of samples at the same time, 
it is particularly useful in detecting 
the spread of the disease in a large 
population within a short span of time. 
Hence, the World Health Organisation 
(WHO) is facilitating this test to 
determine the exposure and spread of 
the disease worldwide.
Parting thoughts
Molecular and antigen tests can help 
control the pandemic by detecting the 
virus in early stages of infection, even 
before its symptoms become evident. 
Antibody tests help determine what 
proportion of a population has been 
exposed to the virus, and how long 
their protection against reinfection 
lasts. The more accurate these tests, 
the more effective they will be in 
combating the pandemic. Many testing 
kits are available, and newer ones 
are constantly being developed. But 
physical distancing, the use of masks, 
and frequent hand washing remain the 
most effective ways to minimise the 
spread of infection.
Box 3. How does an ELISA work? 
In an ELISA, part of the antigen of interest is synthesised and adsorbed onto a base, like 
a plastic strip or a plate with wells (see Fig. 5). In the most common form of the test, the 
blood sample to be tested is diluted with a buffer and added to the plate. The plate is 
incubated to allow time for virus-specific antibodies to attach to the antigen in the plate. It 
is then washed to remove all unbound antibodies.
A second set of antibodies, called capture antibodies, is added to the strip or plate. Each 
capture antibody is linked to an enzyme molecule. Since this second set of antibodies 
is capable of binding to virus-specific antibodies, it will link to any antibody-antigen 
complex on the plate. After washing to remove any unbound material, the substrate for 
the enzyme is added to the plate. The presence of the enzyme linked to the second set 
of antibodies will result in the formation of a coloured product. The intensity of colour 
produced is a measure of the antibody concentration in the blood sample.
Fig. 5. The design of a ‘sandwich’ ELISA.
Credits: Jeffrey M. Vinocur, Wikimedia Commons. URL: https://commons.wikimedia.org/wiki/
File:ELISA-sandwich.svg. License: CC-BY.
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Note: Source of the image used in the background of the article title: https://www.flickr.com/photos/iaea_imagebank/49869473991. Credits: Dean Calma, IAEA 
Imagebank. License: CC-BY.
• COVID-19 is diagnosed by testing for the presence of the virus or the body’s response to infection.
• The usefulness of a test is measured by its specificity and sensitivity. No test is perfect. 
• Molecular tests (real-time and TrueNat) detect genes specific to SARS-CoV-2 in nose or throat 
swabs using a method called Reverse Transcription Polymerase Chain Reaction (RT-PCR). These 
are the most accurate tests available. 
• The Rapid Antigen Test (RAT) detects SARS-CoV-2 specific antigens in nose or throat swabs 
using a method called Lateral Flow Immunoassay. It allows quick screening of contacts of an 
infected person in the trace-test-quarantine protocol. 
• Antibody tests detect IgM and IgG antibodies in blood serum or plasma samples using an 
Enzyme Linked Immunosorbent Assay (ELISA) or a Lateral Flow Immunoassay. These tests are 
particularly useful in population-wide screening, and identification of past infections.
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